Human medicines European public assessment report (EPAR): Nezglyal, leriglitazone, Date of authorisation: 21/09/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Jorveza, budesonide, Date of authorisation: 08/01/2018, Revision: 8, Status: Authorised

Article 57 product data

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Degevma, denosumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Atazanavir Viatris (previously Atazanavir Mylan), atazanavir, Date of authorisation: 22/08/2016, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Givlaari, givosiran, Date of authorisation: 02/03/2020, Revision: 8, Status: Authorised

Sponsor guidance: New safety module on the annual safety report